Mind Medicine (MindMed) (MNMD) Financials

$6.23 -0.20 (-3.11%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.27 +0.04 (+0.64%)

As of 04/25/2025 07:53 PM Eastern

Annual Income Statements for Mind Medicine (MindMed)

This table shows Mind Medicine (MindMed)'s income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-57	-96	-109
Consolidated Net Income / (Loss)	-57	-96	-109
Net Income / (Loss) Continuing Operations	-57	-96	-109
Total Pre-Tax Income	-57	-96	-109
Total Operating Income	-66	-94	-104
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	66	94	104
Selling, General & Admin Expense	30	42	39
Research & Development Expense	36	52	65
Total Other Income / (Expense), net	9.54	-1.87	-4.76
Interest Expense	-1.50	0.92	-0.26
Interest & Investment Income	-	5.58	12
Other Income / (Expense), net	8.04	-6.53	-17
Basic Earnings per Share	($1.84)	($2.44)	($1.54)
Weighted Average Basic Shares Outstanding	30.86M	39.16M	70.46M
Diluted Earnings per Share	($1.84)	($2.44)	($1.54)
Weighted Average Diluted Shares Outstanding	30.86M	39.16M	70.46M
Weighted Average Basic & Diluted Shares Outstanding	38.06M	41.33M	75.37M

This table shows Mind Medicine (MindMed)'s income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-16	-4.90	-25	-29	-18	-24	-54	-5.85	-14	-35
Consolidated Net Income / (Loss)	-16	-4.90	-25	-29	-18	-24	-54	-5.85	-14	-35
Net Income / (Loss) Continuing Operations	-16	-4.90	-25	-29	-18	-24	-54	-5.85	-14	-35
Total Pre-Tax Income	-16	-22	-25	-29	-18	-24	-54	-5.85	-14	-35
Total Operating Income	-17	-14	-21	-29	-22	-22	-22	-24	-25	-32
Total Operating Expenses	17	14	21	29	22	22	22	24	25	32
Selling, General & Admin Expense	9.21	5.07	8.26	14	8.41	11	10	9.81	7.60	11
Research & Development Expense	7.77	8.83	13	15	13	12	12	15	17	22
Total Other Income / (Expense), net	0.50	9.00	-3.95	0.05	3.69	-1.66	-32	19	11	-2.28
Interest Expense	-0.36	-1.08	0.08	0.08	0.33	0.44	0.43	-2.08	0.73	0.66
Interest & Investment Income	-	-	1.36	1.39	1.49	1.35	1.66	3.12	3.51	3.28
Other Income / (Expense), net	0.14	7.92	-5.24	-1.26	2.53	-2.57	-33	13	8.33	-4.90
Basic Earnings per Share	($0.56)	($0.16)	($0.65)	($0.76)	($0.45)	($0.61)	($1.14)	($0.08)	($0.18)	($0.14)
Weighted Average Basic Shares Outstanding	29.30M	30.86M	38.08M	38.58M	39.72M	39.16M	47.86M	71.91M	77.91M	70.46M
Diluted Earnings per Share	($0.56)	($0.16)	($0.65)	($0.76)	($0.45)	($0.61)	($1.14)	($0.26)	($0.27)	$0.13
Weighted Average Diluted Shares Outstanding	29.30M	30.86M	38.08M	38.58M	39.72M	39.16M	47.86M	75.30M	80.24M	70.46M
Weighted Average Basic & Diluted Shares Outstanding	37.57M	38.06M	38.60M	39.72M	40.09M	41.33M	71.87M	72.14M	73.33M	75.37M

This table details how cash moves in and out of Mind Medicine (MindMed)'s business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	8.60	-42	174
Net Cash From Operating Activities	-50	-64	-79
Net Cash From Continuing Operating Activities	-50	-65	-79
Net Income / (Loss) Continuing Operations	-57	-96	-109
Consolidated Net Income / (Loss)	-57	-96	-109
Amortization Expense	3.18	3.26	1.25
Non-Cash Adjustments To Reconcile Net Income	7.26	22	32
Changes in Operating Assets and Liabilities, net	-3.78	6.28	-3.34
Net Cash From Investing Activities	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00
Acquisitions	0.00	0.00	0.00
Net Cash From Financing Activities	59	22	253
Net Cash From Continuing Financing Activities	59	22	253
Repayment of Debt	0.00	-0.84	-0.13
Issuance of Debt	0.00	15	10
Issuance of Common Equity	60	7.53	-10
Other Financing Activities, net	-0.99	0.16	253
Effect of Exchange Rate Changes	-0.31	0.08	-0.03
Cash Interest Paid	0.00	0.53	2.22

This table details how cash moves in and out of Mind Medicine (MindMed)'s business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	49	-12	-13	-13	0.80	-18	153	-9.20	52	-22
Net Cash From Operating Activities	-9.30	-13	-13	-14	-17	-21	-17	-20	-17	-25
Net Cash From Continuing Operating Activities	-9.30	-13	-13	-14	-17	-21	-17	-20	-17	-25
Net Income / (Loss) Continuing Operations	-16	-4.90	-25	-29	-18	-24	-54	-5.85	-14	-35
Consolidated Net Income / (Loss)	-16	-4.90	-25	-29	-18	-24	-54	-5.85	-14	-35
Amortization Expense	0.79	0.79	0.79	0.79	0.79	0.89	0.53	-	-	0.73
Non-Cash Adjustments To Reconcile Net Income	5.80	-6.60	8.95	5.02	1.64	5.90	38	-11	-4.52	8.89
Changes in Operating Assets and Liabilities, net	0.60	-2.13	1.74	9.47	-1.14	-3.80	-0.68	-3.45	1.01	-0.23
Net Cash From Financing Activities	58	0.42	0.58	1.27	17	2.59	169	11	69	3.81
Net Cash From Continuing Financing Activities	58	0.42	0.58	1.27	17	2.59	169	11	69	3.81
Other Financing Activities, net	-1.10	-0.31	0.00	-	0.11	0.05	177	2.88	70	3.81
Effect of Exchange Rate Changes	-0.14	0.06	0.02	0.06	0.03	-0.03	-0.02	0.00	-0.01	0.00
Cash Interest Paid	-	-	0.00	-	0.10	0.43	0.43	0.44	0.67	0.68

This table presents Mind Medicine (MindMed)'s assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	170	125	302
Total Current Assets	146	104	282
Cash & Equivalents	142	100	274
Prepaid Expenses	3.91	4.17	7.88
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	24	21	21
Goodwill	20	20	20
Intangible Assets	3.69	0.53	0.00
Other Noncurrent Operating Assets	0.33	0.22	0.61
Total Liabilities & Shareholders' Equity	170	125	302
Total Liabilities	19	46	61
Total Current Liabilities	18	32	39
Accounts Payable	2.11	4.14	2.01
Accrued Expenses	5.88	12	13
Other Current Liabilities	9.90	16	24
Total Noncurrent Liabilities	1.18	14	22
Long-Term Debt	0.00	14	22
Other Noncurrent Operating Liabilities	1.18	0.03	0.00
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	151	78	241
Total Preferred & Common Equity	151	78	241
Total Common Equity	151	78	241
Common Stock	345	368	640
Retained Earnings	-194	-290	-399
Accumulated Other Comprehensive Income / (Loss)	0.63	0.34	0.82

This table presents Mind Medicine (MindMed)'s assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	181	156	142	142	276	268	320
Total Current Assets	157	132	120	120	255	248	299
Cash & Equivalents	155	129	117	118	252	243	295
Prepaid Expenses	1.83	3.00	2.90	2.39	3.14	4.56	4.07
Other Current Assets	0.17	-	0.00	-	-	0.00	0.00
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	24	23	22	21	20	20	20
Goodwill	20	20	20	20	20	20	20
Intangible Assets	4.48	2.90	2.11	1.32	0.00	0.00	0.00
Other Noncurrent Operating Assets	-	0.30	0.27	0.23	0.14	0.53	0.49
Total Liabilities & Shareholders' Equity	181	156	142	142	276	268	320
Total Liabilities	27	25	36	46	79	66	58
Total Current Liabilities	26	24	35	31	65	42	33
Accounts Payable	0.82	2.32	8.58	7.69	7.60	2.94	2.15
Accrued Expenses	7.47	6.69	9.95	9.96	9.97	8.23	8.80
Other Current Liabilities	18	15	17	14	48	31	22
Total Noncurrent Liabilities	1.28	1.09	0.99	14	14	24	24
Long-Term Debt	-	-	-	14	14	24	24
Other Noncurrent Operating Liabilities	1.28	1.09	0.99	0.35	0.02	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	154	130	106	96	196	202	262
Total Preferred & Common Equity	154	130	106	96	196	202	262
Total Common Equity	154	130	106	96	196	202	262
Common Stock	342	349	354	362	540	552	626
Retained Earnings	-190	-219	-248	-266	-345	-350	-364
Accumulated Other Comprehensive Income / (Loss)	0.74	0.64	0.36	0.78	0.84	0.83	0.82

This table displays calculated financial ratios and metrics derived from Mind Medicine (MindMed)'s official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	39.58%	-76.25%	-22.76%
EBIT Growth	37.88%	-72.23%	-20.02%
NOPAT Growth	29.33%	-41.51%	-10.71%
Net Income Growth	38.95%	-68.55%	-13.52%
EPS Growth	45.88%	-32.61%	36.89%
Operating Cash Flow Growth	-9.42%	-28.37%	-22.94%
Free Cash Flow Firm Growth	57.89%	-33.46%	-40.92%
Invested Capital Growth	-51.59%	-184.80%	-40.29%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	17.72%	-23.82%	-11.88%
EBIT Q/Q Growth	16.91%	-23.02%	-11.67%
NOPAT Q/Q Growth	5.23%	-9.71%	-10.95%
Net Income Q/Q Growth	17.35%	-24.70%	-11.12%
EPS Q/Q Growth	21.70%	-26.42%	-22.22%
Operating Cash Flow Q/Q Growth	-11.12%	-13.62%	-6.44%
Free Cash Flow Firm Q/Q Growth	0.00%	6.92%	-8.24%
Invested Capital Q/Q Growth	1,047.62%	2.76%	-18.90%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	97.44%	95.35%	90.19%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.54%	-83.59%	-68.01%
Cash Return on Invested Capital (CROIC)	-275.70%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-37.54%	-83.59%	-68.01%
Return on Equity Simple (ROE_SIMPLE)	-37.63%	-122.52%	-45.01%
Net Operating Profit after Tax (NOPAT)	-46	-66	-73
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.52%	-26.37%	-21.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-71.22%	-27.63%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-58	-100	-120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-97	-119
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.55	1.88	2.11
Price to Tangible Book Value (P/TBV)	0.65	2.54	2.30
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.18	0.09
Long-Term Debt to Equity	0.00	0.18	0.09
Financial Leverage	-0.91	-0.99	-1.06
Leverage Ratio	1.10	1.29	1.34
Compound Leverage Factor	1.08	1.23	1.20
Debt to Total Capital	0.00%	15.31%	8.30%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	15.31%	8.30%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	84.69%	91.70%
Debt to EBITDA	0.00	-0.15	-0.18
Net Debt to EBITDA	0.00	0.88	2.11
Long-Term Debt to EBITDA	0.00	-0.15	-0.18
Debt to NOPAT	0.00	-0.22	-0.30
Net Debt to NOPAT	0.00	1.30	3.46
Long-Term Debt to NOPAT	0.00	-0.22	-0.30
Altman Z-Score	0.77	-3.34	2.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.16	3.22	7.25
Quick Ratio	7.94	3.09	7.05
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-37	-49	-70
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-53.79	0.00
Operating Cash Flow to Interest Expense	0.00	-69.96	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-69.96	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	8.78	-7.44	-10
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-9.35	-16	-3.00
Enterprise Value (EV)	-59	61	259
Market Capitalization	83	147	510
Book Value per Share	$4.02	$1.95	$3.29
Tangible Book Value per Share	$3.39	$1.44	$3.02
Total Capital	151	92	263
Total Debt	0.00	14	22
Total Long-Term Debt	0.00	14	22
Net Debt	-142	-86	-252
Capital Expenditures (CapEx)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-28	-31
Debt-free Net Working Capital (DFNWC)	128	72	243
Net Working Capital (NWC)	128	72	243
Net Nonoperating Expense (NNE)	10	30	36
Net Nonoperating Obligations (NNO)	-142	-86	-252
Total Depreciation and Amortization (D&A)	3.18	3.26	1.25
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.84)	($2.44)	($1.54)
Adjusted Weighted Average Basic Shares Outstanding	30.86M	39.16M	70.46M
Adjusted Diluted Earnings per Share	($1.84)	($2.44)	($1.54)
Adjusted Weighted Average Diluted Shares Outstanding	30.86M	39.16M	70.46M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	38.06M	41.33M	75.37M
Normalized Net Operating Profit after Tax (NOPAT)	-46	-66	-73
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	-109.13	0.00
NOPAT to Interest Expense	0.00	-71.42	0.00
EBIT Less CapEx to Interest Expense	0.00	-109.13	0.00
NOPAT Less CapEx to Interest Expense	0.00	-71.42	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Mind Medicine (MindMed)'s official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	1.76%	69.56%	-43.44%	-82.82%	-13.95%	-359.83%	-117.70%	62.75%	10.01%	-53.44%
EBIT Growth	1.68%	66.48%	-41.66%	-78.65%	-13.30%	-314.01%	-113.12%	63.72%	13.74%	-50.84%
NOPAT Growth	1.42%	20.84%	-12.74%	-72.25%	-27.28%	-59.74%	-6.43%	16.19%	-14.69%	-46.20%
Net Income Growth	4.13%	70.87%	-34.49%	-71.79%	-8.72%	-386.72%	-119.22%	79.90%	23.65%	-45.58%
EPS Growth	8.20%	73.77%	1.52%	-26.67%	19.64%	-281.25%	-75.38%	65.79%	40.00%	121.31%
Operating Cash Flow Growth	44.60%	-64.04%	-3.61%	8.47%	-78.83%	-60.04%	-24.51%	-44.38%	-3.40%	-23.28%
Free Cash Flow Firm Growth	0.00%	0.00%	102.71%	130.23%	23.32%	277.16%	3,357.74%	-221.09%	-93.05%	-3,030.10%
Invested Capital Growth	0.00%	-51.59%	-94.28%	-158.22%	-726.35%	-184.80%	-4,600.86%	-54.12%	-14.74%	-40.29%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	1.01%	67.65%	-387.35%	-17.16%	38.30%	-30.52%	-129.75%	79.95%	-49.06%	-122.54%
EBIT Q/Q Growth	1.14%	64.48%	-336.22%	-16.64%	37.30%	-29.78%	-124.55%	80.14%	-49.06%	-126.94%
NOPAT Q/Q Growth	-0.24%	18.15%	-50.09%	-39.89%	25.93%	-2.72%	0.00%	-10.15%	-1.37%	-30.94%
Net Income Q/Q Growth	2.78%	70.26%	-406.12%	-17.39%	38.47%	-33.15%	-127.96%	89.24%	-133.75%	-153.88%
EPS Q/Q Growth	6.67%	71.43%	-306.25%	-16.92%	40.79%	-35.56%	-86.89%	77.19%	-3.85%	148.15%
Operating Cash Flow Q/Q Growth	38.54%	-38.21%	-3.75%	-3.86%	-20.09%	-23.68%	19.28%	-20.43%	14.00%	-47.47%
Free Cash Flow Firm Q/Q Growth	64.20%	96.53%	309.11%	1,065.01%	-190.80%	108.01%	3,981.28%	-140.80%	-44.75%	-21.56%
Invested Capital Q/Q Growth	-104.94%	1,047.62%	-89.34%	-1,268.24%	29.95%	2.76%	-465.56%	60.00%	47.84%	-18.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	22.43%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	97.86%	365.37%	95.08%	95.69%	93.91%	96.34%	97.80%	53.00%	83.11%	92.98%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-44.74%	-37.54%	-47.28%	-65.37%	-61.52%	-83.59%	-76.79%	-66.26%	-54.61%	-68.01%
Cash Return on Invested Capital (CROIC)	0.00%	-275.70%	-378.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-44.74%	-37.54%	-47.28%	-65.37%	-61.52%	-83.59%	-76.79%	-66.26%	-54.61%	-68.01%
Return on Equity Simple (ROE_SIMPLE)	-44.74%	0.00%	-48.46%	-71.09%	-79.99%	0.00%	-63.92%	-50.50%	-37.30%	0.00%
Net Operating Profit after Tax (NOPAT)	-12	-9.73	-15	-20	-15	-16	-16	-17	-17	-23
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.95%	3.50%	-8.17%	-7.82%	-2.16%	-7.31%	-21.14%	6.71%	1.96%	-7.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-16.85%	-	-	-	-8.63%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-17	-5.98	-26	-30	-19	-25	-56	-11	-16	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-5.19	-25	-30	-18	-24	-55	-11	-16	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.65	0.55	0.93	1.30	1.30	1.88	1.92	2.56	1.57	2.11
Price to Tangible Book Value (P/TBV)	0.77	0.65	1.12	1.64	1.66	2.54	2.14	2.85	1.69	2.30
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.15	0.18	0.07	0.12	0.09	0.09
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.15	0.18	0.07	0.12	0.09	0.09
Financial Leverage	-1.01	-0.91	-0.94	-0.97	-1.03	-0.99	-1.13	-1.09	-1.05	-1.06
Leverage Ratio	1.18	1.10	1.14	1.20	1.29	1.29	1.32	1.33	1.29	1.34
Compound Leverage Factor	1.15	4.03	1.08	1.15	1.21	1.24	1.29	0.71	1.07	1.24
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	12.78%	15.31%	6.75%	10.72%	8.49%	8.30%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	12.78%	15.31%	6.75%	10.72%	8.49%	8.30%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	87.22%	84.69%	93.25%	89.28%	91.51%	91.70%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.18	-0.15	-0.11	-0.22	-0.23	-0.18
Net Debt to EBITDA	0.00	0.00	0.00	0.00	1.32	0.88	1.87	2.02	2.54	2.11
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.18	-0.15	-0.11	-0.22	-0.23	-0.18
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.23	-0.22	-0.21	-0.38	-0.37	-0.30
Net Debt to NOPAT	0.00	0.00	0.00	0.00	1.73	1.30	3.57	3.46	4.13	3.46
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.23	-0.22	-0.21	-0.38	-0.37	-0.30
Altman Z-Score	1.28	1.79	1.18	-0.15	-0.69	-1.33	1.26	3.66	3.51	3.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.01	8.16	5.50	3.41	3.85	3.22	3.91	5.92	9.00	7.25
Quick Ratio	5.93	7.94	5.37	3.33	3.78	3.09	3.87	5.81	8.88	7.05
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-0.38	0.79	9.26	-8.41	0.67	27	-11	-16	-20
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	10.46	120.22	-25.63	1.53	63.31	0.00	-22.32	-30.07
Operating Cash Flow to Interest Expense	0.00	0.00	-175.41	-179.81	-50.69	-46.84	-38.24	0.00	-23.65	-38.64
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-175.41	-179.81	-50.69	-46.84	-38.24	0.00	-23.65	-38.64
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.93	8.78	0.94	-11	-7.65	-7.44	-42	-17	-8.78	-10
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-0.93	-9.35	-15	-30	-6.73	-16	-43	-5.91	-1.13	-3.00
Enterprise Value (EV)	-55	-59	-8.75	21	21	61	139	299	140	259
Market Capitalization	100	83	121	138	124	147	377	518	411	510
Book Value per Share	$0.36	$4.02	$3.42	$2.75	$2.42	$1.95	$4.10	$2.81	$3.63	$3.29
Tangible Book Value per Share	$0.30	$3.39	$2.83	$2.18	$1.88	$1.44	$3.68	$2.53	$3.36	$3.02
Total Capital	154	151	130	106	110	92	210	226	287	263
Total Debt	0.00	0.00	0.00	0.00	14	14	14	24	24	22
Total Long-Term Debt	0.00	0.00	0.00	0.00	14	14	14	24	24	22
Net Debt	-155	-142	-129	-117	-104	-86	-238	-219	-271	-252
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-14	-21	-32	-29	-28	-62	-37	-29	-31
Debt-free Net Working Capital (DFNWC)	130	128	108	85	89	72	190	206	266	243
Net Working Capital (NWC)	130	128	108	85	89	72	190	206	266	243
Net Nonoperating Expense (NNE)	4.60	-4.83	10	8.70	2.79	8.32	39	-11	-3.67	12
Net Nonoperating Obligations (NNO)	-155	-142	-129	-117	-104	-86	-238	-219	-271	-252
Total Depreciation and Amortization (D&A)	0.79	0.79	0.79	0.79	0.79	0.89	0.53	0.00	0.00	0.73
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.56)	($0.16)	($0.65)	($0.76)	($0.45)	($0.61)	($1.14)	($0.08)	($0.18)	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	29.30M	30.86M	38.08M	38.58M	39.72M	39.16M	47.86M	71.91M	77.91M	70.46M
Adjusted Diluted Earnings per Share	($0.56)	($0.16)	($0.65)	($0.76)	($0.45)	($0.61)	($1.14)	($0.26)	($0.27)	$0.13
Adjusted Weighted Average Diluted Shares Outstanding	29.30M	30.86M	38.08M	38.58M	39.72M	39.16M	47.86M	75.30M	80.24M	70.46M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.16)	$0.00	$0.00	$0.00	($0.61)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.57M	38.06M	38.60M	39.72M	40.09M	41.33M	71.87M	72.14M	73.33M	75.37M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-9.73	-15	-20	-15	-16	-16	-17	-17	-23
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-343.41	-395.34	-58.19	-56.42	-128.16	0.00	-22.65	-56.96
NOPAT to Interest Expense	0.00	0.00	-192.15	-265.31	-46.13	-35.41	-35.81	0.00	-23.87	-34.64
EBIT Less CapEx to Interest Expense	0.00	0.00	-343.41	-395.34	-58.19	-56.42	-128.16	0.00	-22.65	-56.96
NOPAT Less CapEx to Interest Expense	0.00	0.00	-192.15	-265.31	-46.13	-35.41	-35.81	0.00	-23.87	-34.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

When does Mind Medicine (MindMed)'s financial year end?

According to the most recent income statement we have on file, Mind Medicine (MindMed)'s fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Mind Medicine (MindMed)'s net income changed over the last 2 years?

Mind Medicine (MindMed)'s net income appears to be on an upward trend, with a most recent value of -$108.68 million in 2024, rising from -$56.80 million in 2022. The previous period was -$95.73 million in 2023.

What is Mind Medicine (MindMed)'s operating income?

Mind Medicine (MindMed)'s total operating income in 2024 was -$103.92 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $103.92 million

How has Mind Medicine (MindMed) revenue changed over the last 2 years?

Over the last 2 years, Mind Medicine (MindMed)'s total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Mind Medicine (MindMed) have?

Mind Medicine (MindMed)'s total liabilities were at $60.70 million at the end of 2024, a 30.8% increase from 2023, and a 218.2% increase since 2022.

How much cash does Mind Medicine (MindMed) have?

In the past 2 years, Mind Medicine (MindMed)'s cash and equivalents has ranged from $99.70 million in 2023 to $273.74 million in 2024, and is currently $273.74 million as of their latest financial filing in 2024.

How has Mind Medicine (MindMed)'s book value per share changed over the last 2 years?

Over the last 2 years, Mind Medicine (MindMed)'s book value per share changed from 4.02 in 2022 to 3.29 in 2024, a change of -18.0%.

Related Companies

This page (NASDAQ:MNMD) was last updated on 4/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mind Medicine (MindMed) (MNMD) Financials

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mind Medicine (MindMed) (MNMD) Financials

Annual Income Statements for Mind Medicine (MindMed)

Quarterly Income Statements for Mind Medicine (MindMed)

Annual Cash Flow Statements for Mind Medicine (MindMed)

Quarterly Cash Flow Statements for Mind Medicine (MindMed)

Annual Balance Sheets for Mind Medicine (MindMed)

Quarterly Balance Sheets for Mind Medicine (MindMed)

Annual Metrics and Ratios for Mind Medicine (MindMed)

Quarterly Metrics and Ratios for Mind Medicine (MindMed)

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools